Beximco Pharmaceuticals Limited Sponsored GDR RegS (GB:BXP) has released an update.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Beximco Pharmaceuticals Limited reported a notable 13.1% increase in net sales for the year ending June 2024, reaching BDT 44,391.6 million, alongside a significant 29.7% rise in profit after tax. The company launched 30 new products in Bangladesh and expanded its global footprint with new registrations and approvals, including from the US FDA and Australia’s TGA. These achievements, coupled with a 40% cash dividend proposal, highlight Beximco’s resilience and strategic growth in the pharmaceutical sector.
For further insights into GB:BXP stock, check out TipRanks’ Stock Analysis page.